Pharmaceutical

ERLEADA® Outperforms Enzalutamide in Study Johnson & Johnson Johnson & Johnson’s study at the European Congress of Oncology Pharmacy reveals that ERLEADA® (apalutamide) significantly improves overall survival compared to enzalutamide in metastatic castration-sensitive prostate cancer, reducing death risk by 23% at 24 months.
FDA Approves Zenrelia for Itch Control in Dogs with Allergies FDA Zenrelia FDA Approves Zenrelia for Itch Control in Dogs with Allergies. Zenrelia (ilunocitinib tablets) is a new FDA-approved medication for managing pruritus and allergic dermatitis in dogs aged one year and older
FDA Approves Filsuvez®: Birch Triterpenes Gel for EB FDA Betulin FDA approved Amryt Pharma’s Filsuvez® (Birch Triterpenes Gel) for treating Junctional and Dystrophic Epidermolysis Bullosa in patients 6 months and older. Filsuvez® is now a recognized Orphan Drug, Rare Pediatric Disease, and Fast Track therapy, following its EMA approval in June 2022.
FDA Approves Lazertinib and Amivantamab for First-Line NSCLC Treatment FDA The FDA has approved lazertinib (Lazcluze) and amivantamab-vmjw (Rybrevant) for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations. The combination therapy showed significant improvement in progression-free survival in the MARIPOSA trial.
AbbVie Reports Strong Q2 2024 Performance, Adjusts Full-Year EPS Guidance Financial statements AbbVie AbbVie reports Q2 2024 revenue growth of 4.3% to $14.462 billion, driven by Skyrizi and Rinvoq. Despite robust sales, GAAP EPS fell by 32.5% due to IPR&D expenses. Oncology and Neuroscience portfolios also showed solid gains
Pfizer Q2 2024: 14% Growth in Non-COVID Products, Raises Full-Year Revenue Guidance Financial statements Pfizer Pfizer reports a 2% revenue increase in Q2 2024, driven by 14% growth in non-COVID products like Seagen and Vyndaqel. Full-year revenue guidance raised to $59.5-$62.5 billion, with adjusted EPS guidance increased to $2.45-$2.65.
CHMP July 2024 Meeting: 14 New Medicines Recommended EMA CHMP's July 2024 meeting recommended 14 new medicines and 11 indication expansions. Highlights include new treatments for eczema, liver disease, and cancer, plus six biosimilars and one generic.
Abacavir Linked to Higher Cardiovascular Risk NIH New analysis from the REPRIEVE trial reveals that the HIV drug abacavir significantly raises the risk of major cardiovascular events. The study highlights no similar risk with other ARVs.
Johnson & Johnson Receives FDA and EC Approval for SIRTURO® (bedaquiline) Johnson & Johnson Discover how Johnson & Johnson's SIRTURO® achieves full FDA and EC approval, marking a pivotal advancement in treating multidrug-resistant tuberculosis. Explore Phase 3 study findings validating its efficacy and safety.
LG Chem Enters Chinese Osteoarthritis Treatment Market | GuideView LG Chem Discover LG Chem's strategic partnership with Yifan Pharmaceutical to introduce Synovian (Hyruan One), China's first single-injection osteoarthritis treatment. Learn about its efficacy, regulatory approval, and market impact in the KRW 200 billion industry.